Cellectar Biosciences, Inc. reported a strong third quarter in 2025, bolstered by advances in regulatory strategies for its lead asset, iopofosine I-131, and significant progress in its clinical pipelines.

• Received confirmation from the EMA for conditional marketing authorization eligibility for iopofosine I-131, positioning the drug for potential EU approval as early as 2027.
• Plans to submit a New Drug Application (NDA) to the FDA under the accelerated approval pathway, following favorable twelve-month follow-up data from the Clover Wham study.
• Successfully raised approximately $12.7 million in recent financing to strengthen the balance sheet and support ongoing trial initiatives.
• Progressed in early-phase studies of next-generation radiopharmaceuticals CLR125 and CLR225, targeting various solid tumors, with notable presentations at major cancer research conferences.
• Enhanced strategic partnerships discussions aimed at expediting commercialization and securing non-dilutive capital for iopofosine I-131.